INT291342

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 8
Disease Relevance 5.76
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 3
EMPs 1
PMPs 1
thickening 1
Mpeg1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 102 78.04 Quite High
cytokine 30 67.72 Quite High
Pain 6 35.52 Quite Low
Inflammatory response 24 5.00 Very Low Very Low Very Low
imagery 22 5.00 Very Low Very Low Very Low
Inflammatory marker 6 5.00 Very Low Very Low Very Low
Angina 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Acid Reflux 6 99.20 Very High Very High Very High
Infection 144 98.92 Very High Very High Very High
Pathologic Constriction 2 98.84 Very High Very High Very High
Malaria 420 98.80 Very High Very High Very High
Cardiovascular Disorder Under Development 6 98.44 Very High Very High Very High
Cv Unclassified Under Development 12 98.32 Very High Very High Very High
Fever 66 96.36 Very High Very High Very High
Disease 66 89.04 High High
Ovarian Cancer 30 85.76 High High
Hypertrophic Cardiomyopathy 2 83.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As seen in Table 4, mild valvular thickening with stenosis and regurgitation was reported in most patients with the attenuated form of MPS I.
Negative_regulation (attenuated) of MPS in thickening associated with pathologic constriction and acid reflux
1) Confidence 0.40 Published 2007 Journal J Inherit Metab Dis Section Body Doc Link PMC2798132 Disease Relevance 0.72 Pain Relevance 0
In our study, 9 adult patients with the attenuated form of MPS I but without known manifestations of cardiac abnormalities were studied.
Negative_regulation (attenuated) of MPS associated with cardiovascular disorder under development
2) Confidence 0.40 Published 2007 Journal J Inherit Metab Dis Section Body Doc Link PMC2798132 Disease Relevance 0.63 Pain Relevance 0
Plasma MPs levels decrease after anti-malarial chemotherapy
Negative_regulation (decrease) of MPs in Plasma
3) Confidence 0.03 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.76 Pain Relevance 0
The levels of plasma MPs remain unchanged at 7 days post infection; however, as shown in Figure 3, the levels of plasma MPs decreases after 21 days post treatment.


Negative_regulation (decreases) of MPs in plasma associated with infection
4) Confidence 0.03 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.75 Pain Relevance 0.03
The increased levels of PMPs, EMPs and LMPs were confirmed when the absolute number of MPs per ?
Negative_regulation (number) of MPs in PMPs
5) Confidence 0.03 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.95 Pain Relevance 0.03
To confirm if the absolute numbers of plasma MPs were different between malaria patients and healthy donors, as well as to determinate the numbers of plasma MPs per microliter (MPs/?
Spec (determinate) Negative_regulation (numbers) of MPs in plasma associated with malaria
6) Confidence 0.03 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.21 Pain Relevance 0
This results are in line with the observations described here with P. vivax, and by others with P. falciparum [17], which shown that the levels of MPs significantly decrease after 19 - 21 days post treatment.
Negative_regulation (decrease) of MPs
7) Confidence 0.03 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.79 Pain Relevance 0.10
The increased levels of PMPs, EMPs and LMPs were confirmed when the absolute number of MPs per ?
Negative_regulation (number) of MPs in EMPs
8) Confidence 0.01 Published 2010 Journal Malar J Section Body Doc Link PMC2998527 Disease Relevance 0.95 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox